Nivolumab for advanced squamous cell lung cancer: what are the next steps?
Mené sur 117 patients atteints d'un cancer épidermoïde non à petites cellules du poumon de stade avancé et réfractaire, cet essai international de phase II évalue l'efficacité, du point de vue de la proportion de patients avec réponse objective, et la toxicité du nivolumab
Lung cancer treatment is entering a new era. Non-small-cell lung cancer represents 85% of all lung cancers and can be classified in two histological subgroups: squamous cell and non-squamous cell lung cancer. Several advances in the treatment of this aggressive disease have been made over the past decade. In 2005, Shepherd and colleagues reported the primary role of targeting EGFR with tyrosine kinase inhibitors in the management of non-squamous cell lung cancer. Overall survival for patients with non-small-cell lung cancer who have EGFR mutations in exons 19 and 21 greatly improved with the development of treatments such as gefitinib and erlotinib, which have few toxic effects and easy oral administration.
The Lancet Oncology , commentaire, 2014